Last reviewed · How we verify
Atherosclerotic occlusive disease
Approved treatments
- Nexletol · Esperion Theraps Inc
NEXLIZET reduces LDL-C by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Atherosclerotic occlusive disease patent landscape — cliff calendar, originator estates, attackable patents
- Atherosclerotic occlusive disease treatment landscape brief
- Atherosclerotic occlusive disease treatment updates RSS
Frequently asked questions about Atherosclerotic occlusive disease
What drugs treat Atherosclerotic occlusive disease?
Tracked treatments include Nexletol.
What is the treatment for Atherosclerotic occlusive disease?
Standard treatment for Atherosclerotic occlusive disease includes Nexletol. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Atherosclerotic occlusive disease patent cliff · Atherosclerotic occlusive disease CI report
- Treatment: Nexletol · Esperion Theraps Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing